Corcept Therapeutics' average 12-month price target has been raised by analysts, indicating a potential significant upside from its current price. The consensus rating remains a 'Buy,' suggesting continued analyst confidence in the company's future performance.
The filing indicates that the average 12-month price target for Corcept Therapeutics (CORT) has been raised from $141 to $142.6 by five analysts. This update, coupled with a consensus 'Buy' rating from seven analysts, suggests a positive outlook for the company. The implied potential upside of approximately 74% from the November 3, 2026 closing price is a significant factor for investors. This news primarily affects current and potential shareholders of Corcept Therapeutics, potentially leading to increased investor interest and a short-term positive price movement. Long-term implications depend on the company's ability to meet or exceed these analyst expectations. The key opportunity for traders is the potential for capital appreciation based on this revised target and strong analyst sentiment.